journal
MENU ▼
Read by QxMD icon Read
search

Oncology Research and Treatment

journal
https://www.readbyqxmd.com/read/30007958/transarterial-chemoembolization-tace-using-mitomycin-with-or-without-irinotecan-for-hepatocellular-carcinoma-in-european-patients
#1
Tatjana Gruber-Rouh, Ahmed Kamal, Katrin Eichler, Nagy N Naguib, Martin Beeres, Marcel Langenbach, Thomas J Vogl
No abstract text is available yet for this article.
July 16, 2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29975960/evaluation-of-factors-affecting-lymph-node-metastasis-in-clinical-stage-i-ii-epithelial-ovarian-cancer
#2
Baki Erdem, Ilkbal T Yüksel, Nuri Peker, Suat C Ulukent, Osman Aşıcıoğlu, Ipek Y Özaydin, Volkan Ülker, Ozgur Akbayir
No abstract text is available yet for this article.
July 6, 2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29975953/thalidomide-in-combination-with-chemotherapy-in-treating-elderly-patients-with-acute-myeloid-leukemia
#3
Chen Chen, Jing Yang, Wei Xu
No abstract text is available yet for this article.
July 6, 2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29902791/overall-survival-benefit-from-trastuzumab-based-treatment-in-her2-positive-metastatic-breast-cancer-a-retrospective-analysis
#4
Shuzhen Lv, Yunchao Wang, Tao Sun, Donggui Wan, Lijun Sheng, Wei Li, Huayun Zhu, Yanping Li, Janice Lu
No abstract text is available yet for this article.
June 15, 2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29902787/multidisciplinary-late-effects-clinics-for-childhood-cancer-survivors-in-germany-a-two-center-study
#5
Judith Gebauer, Sarah Rieken, Sonja Schuster, Birgit Hahn, Niklas Gebauer, Norbert Meidenbauer, Georg Brabant, Markus Metzler, Thorsten Langer
No abstract text is available yet for this article.
June 15, 2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29902785/dedifferentiated-chondrosarcoma-demonstrating-osteosarcomatous-differentiation
#6
Baljinder S Dhinsa, Mariagrazia DeLisa, Rob Pollock, Adrienne M Flanagan, Jeremy Whelan, Jonathan Gregory
No abstract text is available yet for this article.
June 15, 2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29895025/the-story-of-imatinib-in-gist-a-journey-through-the-development-of-a-targeted-therapy
#7
Peter Reichardt
No abstract text is available yet for this article.
June 13, 2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29895008/the-impact-of-surgical-complications-on-cancer-recurrence-rates-a-literature-review
#8
Suzanne M Beecher, Donal P O'Leary, Ray McLaughlin, Michael J Kerin
No abstract text is available yet for this article.
June 13, 2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29843145/meetings-and-conferences
#9
(no author information available yet)
No abstract text is available yet for this article.
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29843144/erratum
#10
(no author information available yet)
No abstract text is available yet for this article.
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29843143/the-role-of-salvage-high-dose-chemotherapy-in-relapsed-male-germ-cell-tumors
#11
Christoph Oing, Anja Lorch
Germ cell tumors (GCT) are a unique tumor entity with excellent cure rates if guideline-endorsed treatment is thoroughly applied. Even patients with widespread metastatic disease can often be cured with cisplatin-based combination chemotherapy as part of a multimodal treatment approach. However, about 30% of patients with metastatic disease at initial presentation, corresponding to about 5-10% of all GCT patients, relapse or progress despite first-line treatment and therefore require salvage chemotherapy. Salvage systemic treatment either consists of conventional-dose cisplatin-based combination chemotherapy or sequential high-dose treatment with carboplatin and etoposide plus subsequent autologous stem cell support...
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29772568/primary-and-postchemotherapy-retroperitoneal-lymphadenectomy-for-testicular-cancer
#12
Axel Heidenreich, Pia Paffenholz, Tim Nestler, David Pfister
Clinical stage I (CS I) testicular non-seminomatous germ cell tumours (NSGCT) are highly curable. Following orchidectomy, a risk-adapted approach using active surveillance, nerve-sparing retroperitoneal lymph node dissection (RPLND) and primary chemotherapy is recommended by the current guidelines. CS I is defined as showing negative values for tumour markers (or values declining to their half-life following orchidectomy) and negative imaging studies of the chest, abdomen and retroperitoneum. Active surveillance can be performed in low- and high-risk NSGCT with an anticipated relapse rate of about 15% and 50%, respectively...
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29763926/clinical-stage-iia-iic-seminoma-radiation-therapy-versus-systemic-chemotherapy-versus-retroperitoneal-lymph-node-dissection
#13
Gunhild von Amsberg, Robert Hamilton, Alexandros Papachristofilou
BACKGROUND: Clinical stage II (CSII) seminoma is defined by the presence of pure seminoma accompanied by retroperitoneal lymph node metastases. In patients with bulky disease (lymph nodes > 5 cm in diameter), platinum-based chemotherapy is the widely accepted standard of care. However, the optimal choice of treatment for CSIIA and IIB is more controversial. METHODS: We performed a PubMed search using the key words stage II seminoma, BEP (cisplatin, etoposide, and bleomycin), hockey-stick radiotherapy, dog-leg radiotherapy and retroperitoneal lymph node dissection...
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29763922/testis-sparing-surgery-in-patients-with-germ-cell-cancer-indications-and-clinical-outcome
#14
David Pfister, Pia Paffenholz, Friederike Haidl
Testicular cancer affects mainly young men between 20 and 30 years of age. Due to the availability of effective chemotherapy, the majority of patients are cured. Despite an increased risk of metachronous testicular cancer, it should be carefully considered whether immediate orchiectomy is indicated. This mini review gives an account of the available literature on testis-sparing surgery in patients with unilateral or bilateral synchronous or metachronous testicular cancer.
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29763920/interdisciplinary-management-of-testicular-germ-cell-tumors-more-needed-than-ever
#15
Axel Heidenreich
No abstract text is available yet for this article.
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29742518/immune-checkpoint-inhibitors-in-the-treatment-of-patients-with-neuroendocrine-neoplasia
#16
Matthias M Weber, Christian Fottner
BACKGROUND: Well-differentiated neuroendocrine neoplasms (NENs) are usually controlled by antiproliferative, local ablative and/or radionuclide therapies, whereas poorly differentiated NENs generally require cytotoxic chemotherapy. However, treatment options for patients with advanced/metastatic high-grade NENs remain limited. METHOD: Review of the literature and international congress abstracts on the efficacy and safety of immunotherapy by checkpoint inhibition in advanced/metastatic NENs...
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29734197/completion-thyroidectomy-safer-than-thought
#17
Mehmet A Gulcelik, Lutfi Dogan, Gokhan G Akgul, Erhan H Güven, Neşe Ersöz Gulcelik
BACKGROUND: The aim of this study was to find out whether a substantial difference in terms of complication rates exists between primary and completion thyroidectomies following initial bilateral subtotal thyroidectomy in the light of current literature and our series. PATIENTS AND METHODS: Total number of 696 patients who received completion thyroidectomy (Group 1, n = 289) and total thyroidectomy for differentiated thyroid cancer (Group 2, n = 407) and their data were reviewed and postoperative complications were compared between the groups and with the literature...
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29734194/challenges-in-infectious-diseases-for-haematologists
#18
Marie von Lilienfeld-Toal, Georg Maschmeyer
Infections remain a threat for patients with haematological malignancies. In accordance with the European Hematology Association roadmap we provide a concise overview regarding the most relevant current challenges in infectious diseases for haematologists. These include bacterial infections and the need for antibiotic stewardship as well as infections with community-acquired respiratory viruses, infections in patients receiving targeted therapies, re-activations of latent infections and vaccination strategies...
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29734190/severe-pain-due-to-paraspinal-abscess-formation-in-two-patients-with-squamous-cell-carcinoma-of-the-head-and-neck-after-multimodal-treatment-including-cetuximab
#19
Christina Gerlach, Ina Pretzell, Elisabeth Lieberknecht, Stefan Mattyasovszky, Martin Weber
BACKGROUND: Patients with squamous-cell carcinoma of the head and neck (SCCHN) on palliative therapy usually have a bad prognosis and suffer from various symptoms. With increasing use of targeted agents in cancer patients at the end of life, the correct assignment of therapy-related symptoms becomes increasingly difficult as cancer-related symptoms usually increase as well. CASE REPORT: We report on 2 cases of patients with SCCHN who received multimodal treatment including palliative therapy with cetuximab...
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29734184/burden-of-oral-mucositis-a-systematic-review-and-implications-for-future-research
#20
Karin Berger, Dorothee Schopohl, Antonia Bollig, Dorothea Strobach, Christina Rieger, Dale Rublee, Helmut Ostermann
BACKGROUND: Surprisingly little is known about the burden of oral mucositis (OM). We provide a systematic review of studies on the burden of OM (incidence, economic impact, health-related quality of life (HRQoL)). METHODS: Systematic literature searches were made in BIOSIS, EMBASE, and MEDLINE. Inclusion criteria were studies on OM in hematology/oncology patients of ≥ 18 years, journal articles, English language, and published between 2000 and 2016; OM treatment studies were excluded...
2018: Oncology Research and Treatment
journal
journal
48348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"